Croatian
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Pelzont (laropiprant / nicotinic acid) - C10AD52

Updated on site: 09-Oct-2017

Naziv lijekaPelzont
ATK šifraC10AD52
Tvarlaropiprant / nicotinic acid
ProizvođačMerck Sharp

Sadržaj članka

PELZONT

EPAR summary for the public

Pelzont is a medicine containing two active substances: nicotinic acid (also known as niacin or vitamin B3) and laropiprant. It is available as modified-release tablets. ‘Modified-release’ means that the two active substances are released at different rates from the tablet over a few hours.

hypercholesterolaemia’. Patients with combined mixed dyslipidaemia have high blood levels of ‘bad’ LDL cholesterol and triglycerides (a type of fat), and low levels of ‘good’ HDL cholesterol. Primary hypercholesterolaemia is when the levels of cholesterol in the blood are high. Primary means that the hypercholesterolaemia does not have any identifiable cause.

The medicine can only be obtained with a prescription.

Pelzont is normally given together with a statin (the standard medicine used to reduce cholesterol) when the effectivenessMedicinalof a st tin taken alone is inadequate. Pelzont is used on its own only in patients who cannot take statins.

How is Pelzont us d?

The starting dose of Pelzont is one tablet once a day for four weeks, after which the dose is increased to two tablets once day. It is taken by mouth, with food, in the evening or before going to bed. The tablets must be swallowed whole, and should not be split, broken, crushed or chewed.

Pelzont is not recommended for use in children under 18 years of age because of a lack of information on its safety and effectiveness in this group. It should be used with caution in patients who have problems with their kidneys and should not be used in patients with liver problems.

Komentari

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
  • Pomoć
  • Get it on Google Play
  • O nama
  • Info on site by:

  • Presented by RXed.eu

  • 27558

    popisanih lijekova na recept